How to buy Co-Diagnostics (CODX) shares in Australia

Learn how to easily invest in Co-Diagnostics shares.

Co-Diagnostics Inc
NASDAQ: CODX - USD
DIAGNOSTICS & RESEARCH
$9.76
- $0.08 ( - 0.81%)

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Co-Diagnostics Inc is a diagnostics & research business with stocks listed in the US. Co-Diagnostics shares (CODX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$9.76 – a decrease of 2.59% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Co-Diagnostics

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Co-Diagnostics. Find the share by name or ticker symbol: CODX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Co-Diagnostics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$10.98, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Co-Diagnostics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Co-Diagnostics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Co-Diagnostics stock price (NASDAQ:CODX)

Use our graph to track the performance of CODX stocks over time.

Co-Diagnostics shares at a glance

Information last updated 2021-09-24.
52-week rangeUS$7.01 - US$20.685
50-day moving average US$10.3218
200-day moving average US$9.5259
Target priceUS$22.5
PE ratio 5.9951
Dividend yield N/A (0%)
Earnings per share (TTM) US$1.628

Where to buy Co-Diagnostics stock

Name Product Standard brokerage for US shares Currency conversion fee Markets
eToro (global stocks)
US$0
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
US$0
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
US$0
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares
Australia’s lowest-cost broker for ASX shares and ETFs.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
Saxo Capital Markets (Classic account)
US$4
1%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Invest
US$0
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Co-Diagnostics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Co-Diagnostics share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Considering buying Co-Diagnostics shares?

Before you consider Co-Diagnostics, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.

Show me how

Co-Diagnostics price performance over time

Historical closes compared with the last close of $9.76

1 week (2021-09-17) -2.59%
1 month (2021-08-25) -10.70%
3 months (2021-06-25) 14.02%
6 months (2021-03-25) -19.47%
1 year (2020-09-25) -31.94%
2 years (2019-09-25) 795.41%
3 years (2018-09-25) 271.10%

Is Co-Diagnostics under- or over-valued?

Valuing Co-Diagnostics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Co-Diagnostics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Co-Diagnostics's P/E ratio

Co-Diagnostics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Co-Diagnostics shares trade at around 6x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Co-Diagnostics's EBITDA

Co-Diagnostics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$50.4 million (£0.0 million).

The EBITDA is a measure of a Co-Diagnostics's overall financial performance and is widely used to measure a its profitability.

Co-Diagnostics financials

Revenue TTM US$96.3 million
Operating margin TTM 52.1%
Gross profit TTM US$58 million
Return on assets TTM 47.68%
Return on equity TTM 75.16%
Profit margin 47.97%
Book value 3.021
Market capitalisation US$282 million

TTM: trailing 12 months

Shorting Co-Diagnostics shares

There are currently 2.4 million Co-Diagnostics shares held short by investors – that's known as Co-Diagnostics's "short interest". This figure is 23.5% down from 3.1 million last month.

There are a few different ways that this level of interest in shorting Co-Diagnostics shares can be evaluated.

Co-Diagnostics's "short interest ratio" (SIR)

Co-Diagnostics's "short interest ratio" (SIR) is the quantity of Co-Diagnostics shares currently shorted divided by the average quantity of Co-Diagnostics shares traded daily (recently around 1.4 million). Co-Diagnostics's SIR currently stands at 1.67. In other words for every 100,000 Co-Diagnostics shares traded daily on the market, roughly 1670 shares are currently held short.

However Co-Diagnostics's short interest can also be evaluated against the total number of Co-Diagnostics shares, or, against the total number of tradable Co-Diagnostics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Co-Diagnostics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Co-Diagnostics shares in existence, roughly 80 shares are currently held short) or 0.088% of the tradable shares (for every 100,000 tradable Co-Diagnostics shares, roughly 88 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Co-Diagnostics.

Find out more about how you can short Co-Diagnostics stock.

Co-Diagnostics share dividends

We're not expecting Co-Diagnostics to pay a dividend over the next 12 months.

Co-Diagnostics share price volatility

Over the last 12 months, Co-Diagnostics's shares have ranged in value from as little as US$7.01 up to US$20.685. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Co-Diagnostics's is -1.9594. This would suggest that Co-Diagnostics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Co-Diagnostics has bucked the trend.

Co-Diagnostics overview

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant and animal genomes. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site